For the millions of infants in sub-Saharan Africa living under year-round malaria pressure, existing tools—bed nets, seasonal chemoprevention, and even the recently deployed RTS,S vaccine—offer incomplete protection. A rigorously designed Phase 2 trial now suggests a long-acting monoclonal antibody could fill that gap, potentially reshaping how the global health community protects the most vulnerable age group from one of the world's leading childhood killers.
Conducted in Siaya County, western Kenya—a region with intense perennial transmission—the trial enrolled infants and children aged 5 to 59 months in a randomized, double-blind, placebo-controlled design. Across safety-focused early phases using age de-escalation and dose escalation (5–40 mg/kg subcutaneously), L9LS demonstrated an acceptable tolerability profile. In the efficacy phase, children received either two doses of L9LS (10–20 mg/kg at baseline and month 6), a single dose followed by placebo, or placebo at both timepoints, with 12 months of follow-up via monthly blood smear surveillance. The antibody targets the PfCSP circumsporozoite protein of Plasmodium falciparum, blocking hepatocyte invasion before blood-stage infection can establish.
This trial builds on earlier work showing L9LS efficacy in older children (6–10 years) during seasonal transmission in Mali, but testing in perennial settings and younger ages is a critical escalation. Infants under one year are disproportionately harmed by malaria and are precisely the cohort hardest to protect with existing tools. The subcutaneous administration route—rather than intravenous—also improves feasibility for low-resource settings. Key limitations include the Phase 2 scale, meaning the trial was not powered for definitive efficacy endpoints the way a Phase 3 would be, and a single-country design may not generalize across Africa's diverse transmission ecologies. Nonetheless, given the Lancet platform and the rigorous design, this represents a potentially paradigm-shifting step: passive immunization via monoclonal antibodies could one day complement or even substitute for active vaccination campaigns in the highest-burden age groups.